With another earnings season upon us, the Fool's health-care team is busy making sure investors know what to expect from their favorite companies this quarter, while also maintaining a focus on the long term.
In the following video, health-care bureau chief Brenton Flynn outlines some derivative insights from today's Johnson & Johnson earnings call, where he made a number of observations and found implications for Medivation , Zimmer , Stryker , and potentially Abbott Labs .
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.
The article Reading the Johnson & Johnson Earnings Tea Leaves originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.